Donor bone marrow infusion in deceased and living donor renal transplantation

Gaetano Ciancio, George W Burke, Jang Moon, Rolando Garcia-Morales, Anne Rosen, Violet Esquenazi, James Mathew, Yide Jin, Joshua Miller

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The infusion and persistence in a transplant recipient of donor-derived bone marrow cells (DBMC) of multi-lineage can lead to a state of permanent chimerism. In solid vascular organ transplantation, the donor bone marrow lineage cells can even be derived from the transplant organ, and these cells can be detected in very small numbers in the recipient. This has been called microchimerism. Much controversy has developed with respect to the function of chimeric cells in organ transplantation. One idea is that the occurrence of these donor cells found in microchimerism in the recipient are coincidental and have no long-term beneficial effect on engraftment. A second and opposing view, is that these donor cells have immunoregulatory function that affect both the acute and chronic phases of the recipient anti-donor responses. It follows that detecting quantitative changes in chimerism might serve as an indication of the donor-specific alloimmune or regulatory response that could occur in concert with or independent of other adaptive immune responses. The latter, including autoimmune native disease, need to be controlled in the transplant organ. The safety and immune tolerance potential of DBMC infusion with deceased and living donor renal transplants was evaluated in a non-randomized trial at this center and compared with non-infused controls given identical immunosuppression. Overall DBMC infusions were well tolerated by the recipients. There were no complications from the infusion(s), no episodes of graft-vs-host disease (GVHD) and no increase infections or other complications. hi the deceased DBMC-kidney trial, actuarial graft survival at 5 years was superior especially when graft survival was censored for recipient death. Acute rejections were significant reduced in patients given two DBMC infusions, and chronic rejection was dramatically reduced in all DBMC treated patients. The most interesting finding was that the degree of microchimerism slowly increased over the years the DBMC group that had exhibited no rejection episodes. hi the DBMC-living related trial, the incidence of acute rejection did not differ between groups. However, DBMC chimerisin in recipient iliac crest marrow had increased more rapidly than might be predicted from results previously seen in the cadaver group, despite four times fewer DBMC infused, with the generation of T-regulartory cells in-vitro assays.

Original languageEnglish
Pages (from-to)998-1003
Number of pages6
JournalYonsei Medical Journal
Volume45
Issue number6
StatePublished - Dec 31 2004

Fingerprint

Living Donors
Bone Marrow Cells
Kidney Transplantation
Bone Marrow
Tissue Donors
Chimerism
Transplants
Organ Transplantation
Graft Survival
Kidney
Immune Tolerance
Adaptive Immunity
Graft vs Host Disease
Cell Lineage
Cadaver
Immunosuppression
Autoimmune Diseases
Blood Vessels
Safety

Keywords

  • Chimerism
  • Chronic rejection
  • Donor bone marrow infusion
  • Kidney transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ciancio, G., Burke, G. W., Moon, J., Garcia-Morales, R., Rosen, A., Esquenazi, V., ... Miller, J. (2004). Donor bone marrow infusion in deceased and living donor renal transplantation. Yonsei Medical Journal, 45(6), 998-1003.

Donor bone marrow infusion in deceased and living donor renal transplantation. / Ciancio, Gaetano; Burke, George W; Moon, Jang; Garcia-Morales, Rolando; Rosen, Anne; Esquenazi, Violet; Mathew, James; Jin, Yide; Miller, Joshua.

In: Yonsei Medical Journal, Vol. 45, No. 6, 31.12.2004, p. 998-1003.

Research output: Contribution to journalArticle

Ciancio, G, Burke, GW, Moon, J, Garcia-Morales, R, Rosen, A, Esquenazi, V, Mathew, J, Jin, Y & Miller, J 2004, 'Donor bone marrow infusion in deceased and living donor renal transplantation', Yonsei Medical Journal, vol. 45, no. 6, pp. 998-1003.
Ciancio G, Burke GW, Moon J, Garcia-Morales R, Rosen A, Esquenazi V et al. Donor bone marrow infusion in deceased and living donor renal transplantation. Yonsei Medical Journal. 2004 Dec 31;45(6):998-1003.
Ciancio, Gaetano ; Burke, George W ; Moon, Jang ; Garcia-Morales, Rolando ; Rosen, Anne ; Esquenazi, Violet ; Mathew, James ; Jin, Yide ; Miller, Joshua. / Donor bone marrow infusion in deceased and living donor renal transplantation. In: Yonsei Medical Journal. 2004 ; Vol. 45, No. 6. pp. 998-1003.
@article{0588e84598f742dca00a915867aa13d3,
title = "Donor bone marrow infusion in deceased and living donor renal transplantation",
abstract = "The infusion and persistence in a transplant recipient of donor-derived bone marrow cells (DBMC) of multi-lineage can lead to a state of permanent chimerism. In solid vascular organ transplantation, the donor bone marrow lineage cells can even be derived from the transplant organ, and these cells can be detected in very small numbers in the recipient. This has been called microchimerism. Much controversy has developed with respect to the function of chimeric cells in organ transplantation. One idea is that the occurrence of these donor cells found in microchimerism in the recipient are coincidental and have no long-term beneficial effect on engraftment. A second and opposing view, is that these donor cells have immunoregulatory function that affect both the acute and chronic phases of the recipient anti-donor responses. It follows that detecting quantitative changes in chimerism might serve as an indication of the donor-specific alloimmune or regulatory response that could occur in concert with or independent of other adaptive immune responses. The latter, including autoimmune native disease, need to be controlled in the transplant organ. The safety and immune tolerance potential of DBMC infusion with deceased and living donor renal transplants was evaluated in a non-randomized trial at this center and compared with non-infused controls given identical immunosuppression. Overall DBMC infusions were well tolerated by the recipients. There were no complications from the infusion(s), no episodes of graft-vs-host disease (GVHD) and no increase infections or other complications. hi the deceased DBMC-kidney trial, actuarial graft survival at 5 years was superior especially when graft survival was censored for recipient death. Acute rejections were significant reduced in patients given two DBMC infusions, and chronic rejection was dramatically reduced in all DBMC treated patients. The most interesting finding was that the degree of microchimerism slowly increased over the years the DBMC group that had exhibited no rejection episodes. hi the DBMC-living related trial, the incidence of acute rejection did not differ between groups. However, DBMC chimerisin in recipient iliac crest marrow had increased more rapidly than might be predicted from results previously seen in the cadaver group, despite four times fewer DBMC infused, with the generation of T-regulartory cells in-vitro assays.",
keywords = "Chimerism, Chronic rejection, Donor bone marrow infusion, Kidney transplantation",
author = "Gaetano Ciancio and Burke, {George W} and Jang Moon and Rolando Garcia-Morales and Anne Rosen and Violet Esquenazi and James Mathew and Yide Jin and Joshua Miller",
year = "2004",
month = "12",
day = "31",
language = "English",
volume = "45",
pages = "998--1003",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

TY - JOUR

T1 - Donor bone marrow infusion in deceased and living donor renal transplantation

AU - Ciancio, Gaetano

AU - Burke, George W

AU - Moon, Jang

AU - Garcia-Morales, Rolando

AU - Rosen, Anne

AU - Esquenazi, Violet

AU - Mathew, James

AU - Jin, Yide

AU - Miller, Joshua

PY - 2004/12/31

Y1 - 2004/12/31

N2 - The infusion and persistence in a transplant recipient of donor-derived bone marrow cells (DBMC) of multi-lineage can lead to a state of permanent chimerism. In solid vascular organ transplantation, the donor bone marrow lineage cells can even be derived from the transplant organ, and these cells can be detected in very small numbers in the recipient. This has been called microchimerism. Much controversy has developed with respect to the function of chimeric cells in organ transplantation. One idea is that the occurrence of these donor cells found in microchimerism in the recipient are coincidental and have no long-term beneficial effect on engraftment. A second and opposing view, is that these donor cells have immunoregulatory function that affect both the acute and chronic phases of the recipient anti-donor responses. It follows that detecting quantitative changes in chimerism might serve as an indication of the donor-specific alloimmune or regulatory response that could occur in concert with or independent of other adaptive immune responses. The latter, including autoimmune native disease, need to be controlled in the transplant organ. The safety and immune tolerance potential of DBMC infusion with deceased and living donor renal transplants was evaluated in a non-randomized trial at this center and compared with non-infused controls given identical immunosuppression. Overall DBMC infusions were well tolerated by the recipients. There were no complications from the infusion(s), no episodes of graft-vs-host disease (GVHD) and no increase infections or other complications. hi the deceased DBMC-kidney trial, actuarial graft survival at 5 years was superior especially when graft survival was censored for recipient death. Acute rejections were significant reduced in patients given two DBMC infusions, and chronic rejection was dramatically reduced in all DBMC treated patients. The most interesting finding was that the degree of microchimerism slowly increased over the years the DBMC group that had exhibited no rejection episodes. hi the DBMC-living related trial, the incidence of acute rejection did not differ between groups. However, DBMC chimerisin in recipient iliac crest marrow had increased more rapidly than might be predicted from results previously seen in the cadaver group, despite four times fewer DBMC infused, with the generation of T-regulartory cells in-vitro assays.

AB - The infusion and persistence in a transplant recipient of donor-derived bone marrow cells (DBMC) of multi-lineage can lead to a state of permanent chimerism. In solid vascular organ transplantation, the donor bone marrow lineage cells can even be derived from the transplant organ, and these cells can be detected in very small numbers in the recipient. This has been called microchimerism. Much controversy has developed with respect to the function of chimeric cells in organ transplantation. One idea is that the occurrence of these donor cells found in microchimerism in the recipient are coincidental and have no long-term beneficial effect on engraftment. A second and opposing view, is that these donor cells have immunoregulatory function that affect both the acute and chronic phases of the recipient anti-donor responses. It follows that detecting quantitative changes in chimerism might serve as an indication of the donor-specific alloimmune or regulatory response that could occur in concert with or independent of other adaptive immune responses. The latter, including autoimmune native disease, need to be controlled in the transplant organ. The safety and immune tolerance potential of DBMC infusion with deceased and living donor renal transplants was evaluated in a non-randomized trial at this center and compared with non-infused controls given identical immunosuppression. Overall DBMC infusions were well tolerated by the recipients. There were no complications from the infusion(s), no episodes of graft-vs-host disease (GVHD) and no increase infections or other complications. hi the deceased DBMC-kidney trial, actuarial graft survival at 5 years was superior especially when graft survival was censored for recipient death. Acute rejections were significant reduced in patients given two DBMC infusions, and chronic rejection was dramatically reduced in all DBMC treated patients. The most interesting finding was that the degree of microchimerism slowly increased over the years the DBMC group that had exhibited no rejection episodes. hi the DBMC-living related trial, the incidence of acute rejection did not differ between groups. However, DBMC chimerisin in recipient iliac crest marrow had increased more rapidly than might be predicted from results previously seen in the cadaver group, despite four times fewer DBMC infused, with the generation of T-regulartory cells in-vitro assays.

KW - Chimerism

KW - Chronic rejection

KW - Donor bone marrow infusion

KW - Kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=12344250870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344250870&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 998

EP - 1003

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -